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The retina-specific ABC transporter,
ABCA4, is essential for transport of all-trans
retinal from the rod outer segment discs in the
retina and is known to be associated with a
broad range of inherited retinal diseases
including, Stargardt disease (STGD), autosomal
recessive cone rod dystrophy (arCRD) and
fundus flavimaculatus (FFM). A unique feature
of the ABCA subfamily of ABC transporters is
the presence of highly conserved, long
extracellular loops or domains (ECDs) with
unknown function. The high degree of sequence
conservation and mapped disease associated
mutations in these domains suggest an
important
physiological
significance.
Conformational analysis using circular dichoric
spectroscopy of purified, recombinant ECD2
protein demonstrated that it has an ordered
and stable structure comprised of 27±3% αhelix, 20±3% β-pleated sheet, and 53±3% coil.

Significant conformational changes were
observed in disease-associated mutant proteins.
Using intrinsic tryptophan fluorescence
emission spectrum of ECD2 polypeptide, we
have demonstrated that this domain specifically
interacts with all-trans retinal with a Kd of 1.3 x
10-7 M. Furthermore, the retinal interaction
appeared specific for the all-trans isomer, and
was directly measurable through fluorescence
anisotropy analysis of all-trans retinal. This
interaction was impaired in mutant ECD2
proteins. In summary, our results demonstrate
that the three macular degeneration-associated
mutations lead to significant changes in the
secondary structure of the ECD2 domain of
ABCA4, as well as in its interaction with alltrans-retinal.
ABC transporters are required for
transport of a wide variety of hydrophobic
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substances across cellular membranes, including
drugs (1-3), lipids (4-6), metabolites, peptides (7),
and steroids (2). Typically, eukaryotic ABC
proteins are comprised of two tandem sets of six
transmembrane helices followed by a Walker type
A and a type B nucleotide-binding motif (8). To
date, 48 members of the human ABC transporter
family have been identified, which, based on
sequence homology, have been divided into seven
subfamilies, ABCA through ABCG (2-3,9).
A retina specific variant of the ABCA
subfamily, the ABCA4 gene product (ABCR) was
first described as the bovine and Xenopus Rim
proteins identified in the rims of the rod outer
segment (ROS) discs (10-11). Mutations in the
ABCA4 gene appear to lead to defects in the
energy-dependent transport of all-trans retinal and
lead to the accumulation of cytotoxic lipofuscin
fluorophores in the retinal pigment epithelium
characteristic of the diseases such as Stargardt
disease (STGD), fundus flavimaculatus (FFM) and
autosomal recessive cone-rod-dystrophy (arCRD),
as well as increased susceptibility to age-related
macular degeneration (AMD) (12-20). Although
ultimately these diseases await the promise of a
cure through gene therapy (21-22), current
treatments have been directed towards slowing the
progression of the disease. Consequently,
understanding how genetic mutations lead to
retinal degeneration is critical for the development
of experimental therapies.
Studies in several laboratories and the
establishment of ABCA4 screening consortiums
have aided in the identification of over 500
mutations in ABCA4 gene that are associated with
a plethora of visual diseases. A genotyping
microarray chip has been developed for the
ABCA4 gene which can robustly identify >98% of
the existing mutations (23). Disease-associated
ABCA4 alleles have shown an extraordinary
genetic heterogeneity. Some of these mutations
map to the nucleotide binding domains (NBDs),
suggesting that the underlying defect has a basis in
nucleotide hydrolysis and/or aspects of energy
transduction related to transport. However, the fact
that ABCA4 mutations occur throughout the entire
open reading frame, suggest that defects in ATP
hydrolysis only are one of the causes of these
diseases. At present, the biochemical basis of
functional defects due to mutations in domains
other than the NBDs remain refractory to

biochemical analysis, primarily because these
domains lack any known enzymatic function.
Structural topology varies significantly
between the eight subclasses of ABC transporters.
In the ABCA subfamily each half transporter
contains a transmembrane domain (TMD)
comprised of six membrane spanning units,
followed by a cytoplasmic or soluble domain. In
addition, each ABCA half transporter possesses a
large extracellular loop, which is characteristic of
this subfamily. In the case of ABCA4, several
models of membrane topology have been proposed
based on hydropathy profiles, and experimental
data supports the notion that two large
extracellular domains (ECDs) are present (24).
The EC loops project from TMD1 for ECD1 and
from TMD7 for ECD2; they represent
significantly large polypeptide domains, with 603
residues for ECD1 (aa 43–646) and 285 residues
for ECD2 (aa 1395–1680). The high degree of
sequence conservation observed in the ECDs of
vertebrate ABCA4 proteins suggests an important
physiological significance (20,25).
In the absence of any known enzymatic or
functional motif, it has been difficult to assess the
significance of disease-associated mutations in the
ECD domains of ABCA4. Expression and
characterization of individual functional domains
has been demonstrated to be a viable approach
utilized by several laboratories working with other
ABC proteins, such as the MDR1 and CFTR
transporters (26-29). ABCA4 is a particularly
large membrane protein (~220 kDa), which is
fairly unstable as a recombinant whole molecule.
Consequently, systematic analysis of the structure
and function of each individual domain in
recombinant form is a highly viable and specific
approach, as demonstrated by our previous studies
with the NBD1/NBD2 domains of ABCA4.
Previously, we were able to delineate the structural
and functional specificities of the individual
nucleotide binding domains which would not have
been possible using the full-length ABCA4 protein
(30-32).
Fluorescence and CD spectroscopic
methodologies have been utilized as valuable tools
for the characterization of structure and function
of a variety of proteins including ABC transporters
(33-35). In this report we have employed these
techniques to elucidate the structural features and
functional properties of the second extracellular
2

loop of ABCA4 as well as to delineate the effects
of disease-associated mutations in the ECD2
domain.

Table 1. The authenticity of the mutations and the
absence of other fortuitous mutations were
confirmed by DNA sequencing carried out by
Eurofins MWG/Operon (Huntsville, AL).
Over Expression of pET30b-ECD2 in E. coli. E.
coli cells (strain BL21-CodonPlus(DE3)-RILP;
Stratagene; LaJolla, CA) harboring pET30b-ECD2
plasmid were used to produce the recombinant
ECD2 polypeptide following the manufacturer’s
instructions.
The expressed recombinant
polypeptide appeared to be of the anticipated size
(34 kDa), as determined by SDS−PAGE (Fig. 3A).
Extraction and Purification of Recombinant ECD2
Proteins—Extraction and purification of wild-type
ECD2 protein carrying the S-tag using
immobilized S-protein agarose affinity resin
(EMD Chemicals; Gibbstown, NJ) following the
manufacturer’s recommendations as previously
described (30).
Purification of ECD2 Polypeptide from
Solubilized Inclusion Bodies. Introduction of
mutations into wild-type ECD2 polypeptide
appeared to decrease the solubility of the
expressed proteins as determined by SDS-PAGE
and Western blot procedure (data not shown).
Consequently, we explored the extraction of
recombinant proteins (wild-type and mutants)
from the inclusion bodies followed by refolding.
(37) This approach has been shown to be highly
successful in the purification of a number of ABC
transporters (32,38-40).
The wild-type and mutant ECD2 proteins
were extracted from inclusion bodies using a
protocol, which combines the use of BugBuster
protein extraction reagent (Novagen, Madison,
WI) to process the insoluble fraction and yield
purified inclusion bodies, with the method
described by Booth et al. (32,38,41). After
harvesting the expressed proteins, the cell pellets
were resuspended in room temperature BugBuster
reagent, and protease inhibitors were added. After
incubation on ice for 30 minutes, the cell
suspension was centrifuged to collect purified
inclusion bodies. Following cell lysis, the pellet of
inclusion bodies was resuspended in buffer B and
centrifuged once more. The inclusion body
proteins were solubilized in Buffer C. Protein
refolding was achieved by rapid dilution in Buffer
D. The renatured protein was sequentially dialyzed
in Buffer E. After overnight dialysis, proteins were
concentrated to ~0.5 mg/ml by ultrafiltration

EXPERIMENTAL PROCEDURES
Nucleic Acids, Enzymes, and Other Reagents. The
pRK5 plasmid containing the full-length, wildtype cDNA of the human ABCA4 gene was
obtained as a generous gift from Drs. J. Nathans
and Michael Dean of Johns Hopkins University
(Baltimore, MD) and NCBI (Frederick, MD)
respectively. The T7 expression system vector
pET30b, Bug Buster protein extraction reagent,
Benzonase nuclease and the S-protein agarose
affinity resin were from Novagen (EMD Sciences;
Briggstown, NJ). All-trans retinal was from
Sigma/Aldrich (St. Louis, MO) while 11-cis
retinal was synthesized by Toronto Research
Chemicals, Canada.
Buffers -- Buffer A was 20 mM Tris-HCl (pH 8.0),
100 mM NaCl, 2 mM dithiothreitol, and 15% (v/v)
glycerol. Buffer B contained 20 mM Tris-HCl (pH
7.5), 1 mM MgCl2, 50 mM NaCl, 5% glycerol, and
0.01% Nonidet P-40. Buffer C was 6 M guanidine
hydrochloride, 0.1 M Tris-HCl (pH 8.0), and
2 mM EDTA. Buffer D contained 0.1 M Tris-HCl
(pH 8.0), 0.5 M L-arginine, and 2 mM EDTA.
Buffer E contained 10 mM NaPO4 (pH 7.4),
100 mM NaCl, and 2 mM dithiothreitol.
Design and Cloning of the Construct Containing
ECD2. The ECD2 construct was amplified from
full-length ABCA4 cDNA and cloned into
pET30b T7-expression vector (EMD Sciences;
Briggstown, NJ) using standard recombinant DNA
technology (36). This domain corresponds to a
31.8 kDa (285 aa) polypeptide. The cloning was
designed such that the polypeptide was produced
as a S-tagged fusion protein, leading to a predicted
mass of 34.4 kDa for the recombinant ECD2. For
subsequent recombinant protein expression, the
plasmid was used to transform E. coli strain BL21CodonPlus(DE3)-RILP
competent
cells
(Stratagene, La Jolla, CA).
In Vitro Site-directed Mutagenesis of the ECD2
Construct. Site-directed mutagenesis was carried
out using a PCR based mutagenesis kit
(Stratagene, La Jolla, CA) (32) and the pET30ECD2 plasmid as template. The complementary
oligonucleotides used as mutagenic primers to
generate the mutant ECD2 proteins as detailed in
3

y = ymin + (ymax - ymin)/[1 + 10(logKd – X)]

(Amicon/Millipore). Overall the inclusion body
protein purification methodology described here
yielded highly concentrated, purified, and
homogeneous preparations of protein. The yield
of ECD2 protein was >10 mg from 4 liters of
induced cell culture. Purified proteins were stored
at−80 °C until use.
Circular Dichroism Spectropolarimetry. Spectra
were collected on a Jasco-810 spectrapolarimeter
(X-Ray and Structure Core Facility of
ThomasJefferson University) using a 5 mm path
length cell, and the temperature was maintained at
25°C, or indicated temperature, using a Pelltier
controlled cell holder. Spectra were the average of
five scans collected at a speed of 10 nm min -1.
CD spectra were analyzed using the K2D2 neural
network
based
method
with
its
(http://www.ogic.ca/projects/k2d2/),
associated web server to estimate protein
secondary structure (42-43).
For thermal melting experiments, the
ellipticity at 220 nm was monitored over a
temperature range of 20-80°C, using a resolution
of 0.2°C, a bandwidth of 1 nm, and a temperature
gradient of 1°C min -1. Global analysis of the data
was conducted using the PRISM program
(GraphPad Software, Inc.).
Steady-State
Fluorescence
MeasurementsFluorescence experiments were performed using a
Fluorolog-2 spectrofluorometer (Jobin Yvon
Horiba Inc., Edison, NJ), and measurements were
made in an L-format configuration of excitation
and emission channels. The excitation wavelength
was set to 295 nm to avoid excitation of either
tyrosine or phenylalanine residues. Emission was
scanned from 320 to 400 nm. Excitation and
emission slits were set at 8 nm and 4 nm
respectively. The spectra of the ECD2 polypeptide
were measured in a 0.1 mg/ml solution in buffer E.
Changes in steady state fluorescence were used to
monitor interaction with all-trans and 11-cis retinal
over a concentration range of 0-15 µM. Titrations
with increasing amounts of all-trans retinal were
conducted and emission scans from 320 to 400 nm
were taken at each concentration. Fluorescence
data were normalized to 0-100 arbitrary units for
wild type ECD2 and each mutant. A semilog plot
of emission at 333 nm versus log [all-trans retinal]
was fitted to the sigmoidal dose-response
equation:

where y is the fluorescence intensity and x is the
log of the all-trans retinal concentration.
Anisotropy
values
were
expressed
as
millianisotropy, or mA (anisotropy divided by
1000). The standard error for the measured
anisotropy values was ± 3 mA. An anisotropy
reading for each titration point was taken three
times for 10 s and averaged. The total fluorescence
intensity did not change significantly with an
increase in the ECD2 concentration. Therefore,
fluorescence lifetime changes, or the scattered
excitation light, did not affect the anisotropy
measurements. Anisotropy, A, is defined as
A = (Ivv - GIvh)/(Ivv + 2GIvh)

(1)

where G is the instrumental correction factor for
the fluorometer, and it is defined by,
G = Ihv/Ihh

where, Ivv, Ivh, Ihv, and Ihh represent the
fluorescence signal for excitation and emission
with the polarizers set at (0°, 0°), (0°, 90°), (90°,
0°), and (90°, 90°), respectively.
The interaction of ECD2 with all-trans retinal
(ATR) can be represented as
ECD2 + ATR ´ ECD2∑ATR

(2)

At equilibrium, Ka, the equilibrium association
constant, can be given as
Ka = [ECD2∑ATR]/[ECD2][ATR]

(3)

Ka = [ECD2][ATR] = [ECD2∑ATR]

(4)

The fraction of the binding sites occupied can be
represented as
f = [occupied binding sites]/[total binding sites] =
[ECD2∑ATR]/[ECD2] + [ECD2∑ATR] (5)

Substituting for [ECD2] and rearranging the
equation, we get
f = Ka(ECD2)/[1 + Ka(ECD2)]
(6)
f = [ECD2]/([ECD2] + 1/Ka)
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(7)

The long extracellular (EC) loops, or
domains, are a distinctive topological feature of
the ABCA subfamily of transporters, yet at the
present time their structure and function remain
unknown. Based on current models (Fig. 1), the
ECD1 domain of ABCA4 is defined as projecting
from TMD1 (aa 43-646) while ECD2 projects
from TMD7 (aa 1395–1680). We have calculated
the grand average of hydropathicity indexes
(GRAVY) for ECD1 and ECD2.
GRAVY
analysis of the domains were found to be -0.294
and -0.356 for ECD1 and ECD2, respectively
(ProtParam; ExPASy Proteomics Server). A
negative value corresponds to a hydrophilic
polypeptide while a positive value corresponds to
hydrophobic polypeptide, thus the values are
consistent with the postulated projection of these
domains into the aqueous environment of the
lumen of the rod outer segment discs (Fig. 1) (49).
Stargardt Disease Mutations Affecting Conserved
Residues of ECD2. Several macular degenerative
disease associated mutations map to the ECD2
domain of ABCA4 (13,23,50-52), pointing to its
likely significance ABCA4 function. Three
ABCA4 mutations associated with Stargardt
disease, W1408L, R1443H, and C1488R, were
chosen for analysis in this study. These missense
mutations have been observed to occur in patients
as simple and/or compound heterozygotes (Table
1). Sequence alignments of the ECD2 domains of
ABCA4 proteins were carried out in order to
determine the degree of conservation of these
specific amino acid residues among the ECDs of
several organisms. All three of the mutations
correspond to strictly conserved amino acids in
vertebrate ABCA4 proteins (Fig. 2).
Conformational Analysis of Native and Refolded
ECD2 Polypeptides Suggest a Highly Ordered
Structure: The structural characteristics of native
and refolded recombinant ECD2 polypeptides
were evaluated by comparing their CD spectra in
the far ultra-violet region (200-250 nm). Highly
purified homogenous preparations of recombinant
ECD2 protein was used for CD analysis (Fig. 3).
Secondary structures were determined using K2D2
neural
network
based
analysis
(http://www.ogic.ca/projects/k2d2/ ) (42).
The CD spectra of the native and refolded
ECD2 polypeptides are presented in Fig. 4. The
two spectra were essentially identical and were
typical of structurally ordered proteins, containing

Similarly, the equilibrium dissociation constant Kd
(Kd )1/Ka) can be expressed as
f = [ECD2]/([ECD2] + Kd)

At f = 0.5
Kd = [ECD2]

Thus, Kd can be further defined as the protein
concentration at which half of the sites are
occupied when the ligand concentration is constant
as in the present case or the ligand concentration at
which half of the sites are occupied when the
protein concentration is constant. Global analysis
of the data was conducted using BIOEQS and/or
PRISM (Graphpad Software Inc., San Diego, CA)
programs using a monomer ligand binding model
(44-45). BIOEQS calculates the concentration of
various species in the equilibrium-binding curve
numerically using a constrained optimization
algorithm in which the mass balance constraints
are incorporated as Lagrange multipliers (37). The
program then relates this species concentration
vector to the anisotropy observed at each point in
the titration and fits the free energy and plateau
values by adjusting these floating parameters using
a Marquardt-Levenberg nonlinear least squares
algorithm (46).The Kd values, i.e., the
concentrations of ECD2 required to bind 50% of
the all-trans retinal, were computed using the
equation:
Y = Amin + (Amax - Amin)/(1 + 10(X -X)n
0

app

)

(10)

where Amin and Amax are the anisotropy values at
the bottom and top plateaus, respectively, X
represents the log of the NBD1 concentration, X0
is the X value when the response is halfway
between the top and the bottom, and napp is the Hill
coefficient.
Other Methods. Routine protein concentrations
were determined by the method of Bradford (47)
using bovine serum albumin as a standard, and for
the CD/fluorescence studies using molar extension
coefficient measurements εECD2 = 49,180.
SDS−PAGE was carried out as described by
Lamelli (48).
RESULTS

5

α-helical, β-sheet, and extended coil structures.
Both CD spectra had two minima observed at 208
and 222 nm, characteristic of α-helical structure
(Fig. 4). Nonlinear regression analysis of the CD
spectra provided an estimation of ECD2 secondary
structure; 26±3 % α-helix and 23±3% β-sheet,
respectively (Table 2). These results suggest that
the structure of the refolded ECD2 polypeptide is
essentially the same as that of the native ECD2
protein.
We have analyzed changes in the
conformation of ECD2 protein harboring disease
associated mutations, W1408L, C1488R, and
R1443H. The secondary structures of these
proteins were then compared with that of the wild
type polypeptide (Figs. 5 & 6).
W1408L Mutation – The W1408L mutation has
been reported in several studies investigating the
ABCA4 genotype of individuals afflicted with
Stargardt disease, fundus flavimaculatus and cone
rod dystrophy (13,19,51). This mutation has been
identified in patients with and without the
occurrence of a second ABCA4 mutation
occurring in trans. Alone, this mutation leads to
late onset (30 years of age) of Stargardt disease,
whereas, patients harboring a second ABCA4
mutation in trans may manifest as early onset (12
years of age) of the disease. The Trp→Leu
mutation represents a relatively significant
mutation, in terms of structure and polarity. In
addition, the aromatic residue, with its large
hydrophobic surface present in tryptophan,
represents a potential “hotspot” for protein-protein
and protein-ligand interactions and thus may alter
the biological function of this domain (53). The
far-UV CD spectrum of the mutant ECD2 was
similar to that of the wild type protein suggesting
that this mutant maintained most of the secondary
structural features associated with wild type
ECD2, (Fig. 5). Nonlinear regression analysis
using the K2D2 algorithm of the CD spectrum
indicated the following conformation: 23% αhelix, 24% β-sheet, and 53% coil (Table 3).
Analysis of the thermal melting of ECD2
protein as demonstrated that the ellipticity
measured at 220 nm increased with increase in
temperature, consistent with what would be
expected to accompany protein unfolding in a αhelix to coil transition (Fig. 6A).
In the
temperature range of 20°C to 80°C, the plot for the
wild-type ECD2 protein fitted well to a sigmodial

curve (Fig. 6A inset) and the Tm was 49.8°C
(Table 3). The thermal melting profile of the
W1408L is shown in Fig. 6B. This mutant
appeared more resistant to thermal denaturation
than wtECD2, indicated by a Tm of 57.1°C (Table
3). Therefore, CD and thermal melting
experiments suggest that the wild type and mutant
polypeptides have relatively similar secondary
structure compositions at 25°C, although a higher
Tm may indicate a decreased structural flexibility.
C1488R Mutation - The C1488R mutation has
been identified as a Stargardt disease-linked
mutation in individuals of Northern and Central
European ancestry (13,23,50). This mutation has
been reported to occur in the ABCA4 gene as an
individual heterozygous mutation as well as in
trans with G863A mutation. This mutation
represents a chemically significant substitution of
a basic residue for a strictly conserved cysteine
residue. The far-UV CD spectrum of C1488R
mutant at 25°C is presented in Fig. 5. Nonlinear
regression analysis of the CD spectrum using
K2D2 algorithm indicated the following
conformation: 20% α-helix, 27% β-sheet, and
53% coil (Table 3). Although a dramatic change in
the overall CD spectrum of the protein was not
observed, the substitution resulted in a significant
alteration in the Tm, from 49.8°C to 66.7°C, as
determined by thermal denaturation CD spectra
(Fig. 6C & Table 3). The sudden increase in Tm of
this mutant is not simply an indication of structural
stability; rather it may signify loss of flexibility in
the structure of this domain. A certain degree of
structural flexibility may be important for its
function. Introduction of the charged arginine
residue at this location could lead to abnormal salt
bridge formation, which would support this
hypothesis.
R1443H Mutation - The R1443H mutation has
been identified in individuals with Stargardt
disease and appears to occur in those with
Northern European as well as East Indian ancestry
(23,54).
From a biochemical perspective,
Arg→His represents a change from a highly basic
residue, to an almost neutral residue, and thus
represents a potentially significant change in terms
of physico-chemical properties. The CD spectrum
of this mutant was significantly altered (Fig. 5).
Major shifts in the CD spectral minima at 208 and
220 nm for R1443H were observed at 25°C,
consistent with a helix-coil transition concomitant
6

with a significant change of overall secondary
structure (Fig. 5). Analysis of the spectra using
the K2D2 method shows that the polypeptide had
relatively little α-helical content, ~11%, as
compared to 25% in wild-type ECD2 (Table 3).
Comparing the spectra of the native and heatdenatured states of the R1443H mutant, it appears
that the heat-induced alterations of the secondary
structure elements over the temperature range of
20-80○C were small. It is likely that the absence of
a sequential loss of structure with temperature may
simply reflect the lack of α-helical structure of
R1443H relative to wtECD2.
The ECD2 Domain Specifically Interacts with alltrans Retinal. ABCA4 is believed to function
primarily in the transport and recycling of all-trans
retinal produced in the ROS discs during the visual
transduction cycle (55). The ECD2 domain may
have a number of different roles in the function of
ABCA4. Our hypothesis is that it may play a role
in the interaction of ABCA4 with retinal. In this
study, we had the opportunity to study the ECD2
domain separate from the rest of the ABCA4
molecule. Therefore, we have utilized this model
system to examine ECD2 interaction with retinal.
We observed a significant change in the
tryptophan fluorescence emission spectrum of
ECD2 protein upon retinal addition and the change
was dose-dependent. We have used this as a
fluorescence-based assay to investigate interaction
of retinal derivatives with the ECD2 domain.
Inspection of the primary sequence of
ECD2 shows that seven tryptophan residues are
present in this domain. These residues provide an
indicator of their surroundings as their
fluorescence emission is attenuated in response to
a shift from hydrophobic to hydrophilic
environments as a consequence of conformational
change (56). Changes in protein confirmation as a
result of ligand binding or amino acid substitutions
can thus be monitored. The fluorescence spectra
of wild-type ECD2 polypeptide was collected at
25°C as described in “Experimental Procedures”
in the absence and presence of all-trans retinal
over a concentration range of 0-15 µM. ECD2
displayed a strong emission maximum at 335 nm,
characteristic of tryptophan residues in a
hydrophobic environment (Fig 7A). Upon titration
with all-trans retinal, the tryptophan emission
maxima at 335 nm decreased in a dose-dependent
manner and appeared to saturate at a concentration

of 10 µM retinal (Fig 7A). We have examined
fluorescence properties of all-trans retinal in the
300-400 nm range in order to examine the
possibilities of inner-filter effects or fluorescence
resonance energy transfer (FRET). All-trans
retinal did not show any detectable absorption or
emission in this wavelength range. These results
indicated (1) the ECD2 polypeptide bound alltrans retinal, and (2) the binding accompanied
concomitant conformational changes and/or
changes in tryptophan environment. A semi-log
plot of the attenuated fluorescence intensities at
different all-trans retinal concentrations is shown
in Fig. 8. The plot was fitted by non-linear
regression using PRISM 5.0 to sigmoidal doseresponse
as
detailed
in
“Experimental
Procedures”. The Kd (or EC50) was determined to
be 1.3 ± 1.1 x 10-7 M for wild-type ECD2 protein.
In contrast to all-trans retinal, 11-cis
retinal had only minor effects on the tryptophan
emission spectrum of ECD2 in the same
concentration range (Fig. 9). Although some
changes with increasing concentrations of 11-cis
retinal were observed, perturbations in the
emission spectra were far less significant than that
observed with all-trans retinal. Thus, either the
binding of 11-cis retinal was far weaker than alltrans retinal or the binding of 11-cis retinal did not
elicit the same extent of conformational changes
as all-trans retinal binding. In either case, the
effects of all-trans retinal are distinct from 11-cis
retinal.
Our results indicated that all-trans retinal
elicited a significant effect on the tryptophan
emission spectrum of wild-type ECD2 protein.
Therefore, we examined its effect on the
tryptophan emission spectra of the three Stargardt
mutants (Figs. 7B-D).
Varying degrees of
quenching of their intrinsic
tryptophan
fluorescence was observed in the presence of alltrans retinal, suggesting altered modes of binding
in the mutants. With both W1408L and C1488R,
attenuation of tryptophan fluorescence emission
was observed with increasing concentrations of
all-trans retinal (Fig. 7 B&C), albeit significantly
diminished compared to that observed with the
wild-type ECD2 (Figs. 7A). On the other hand,
mutant Arg1443His displayed little change in
tryptophan fluorescence spectra in the presence of
all-trans retinal, which would indicate that this
mutant did not undergo all-trans retinal binding
7

and/or
associated
conformational
change.
Quantitative analysis of all-trans retinal binding
with these three ECD2 mutants is shown in Fig. 8.
The Kd values for W1408L and C1488R were 8.1
x 10-7 M and 6.7 x 10-7 M, respectively.
Compared to the wild-type ECD2, the binding of
all-trans retinal by these mutants was significantly
weaker. With R1433H mutant, the Kd value could
not be determined and was estimated it to be >30
µM.
Fluorescence Anisotropy Analysis of the
Influence of the R1433H Mutation on all-trans
Retinal Binding. Intrinsic tryptophan fluorescence
analyses in the presence of all-trans retinal were
indicative of conformational change, which in turn
was suggestive of ECD2 protein-ligand
interaction. Thus it was of interest to demonstrate
direct binding of all-trans retinal to this domain.
We have utilized fluorescence anisotropy analysis
to evaluate all-trans retinal binding. Fluorescence
anisotropy is normally used for direct
measurements of ligand binding by determining
the concentrations of bound and free ligand in
solution due to differences in anisotropy values
between bound and free ligand (44-45,57-58).
Therefore, true equilibrium measurements are
possible in this procedure without needing to
isolate the protein•ligand complex from the free
ligand. Due to its structural features, all-trans
retinal is a natural fluorophore.
In order to determine the appropriate
emission/excitation parameters to use in
anisotropy studies, emission spectra of 100 nM alltrans retinal following excitation at 310 nm were
collected over the range 370-570 nm. All-trans
retinal displayed an emission maximum at 430 nm
(Fig. 10A) and thus anisotropy was measured
using 100 nM all-trans retinal with the
wavelengths set at 310 nm for excitation and 430
nm for emission. The fluorescence anisotropy
changes with ECD2 protein concentration are
shown in Fig. 10B. For wild-type ECD2 protein, a
sigmoidal semilog plot was obtained indicating
equilibrium saturation binding of all-trans retinal
by this protein. Clearly, the binding of the
R1433H mutant was impaired relative to that of
the wild type protein, as indicated by its inability
to achieve saturation. The plots, shown in Fig.
10B, were generated by nonlinear regression
analysis of the data using commercial graphing
software (PRISM, GraphPad Inc.). The binding

parameters were determined from the fluorescence
anisotropy data by equilibrium binding analysis
and fitted to Equation 3, using the BIOEQS
program (45). This nonlinear regression analysis
gave a dissociation constant (KD) for ECD2 of 4.0
± 1.3 x 10-7 M for the wild type protein.
DISCUSSION
The ABCA4 protein is an essential
component of the visual signal transduction cycle
in rod and cone cells of vertebrate retina.
Currently no direct assay for measurement of
ABCA4 mediated transport is available. However,
ABCA4 knock-out mice, as well as patients
harboring mutations in ABCA4, display
accumulation of all-trans retinal and Nretinylidene-PE in rod photoreceptor disc
membranes, providing evidence that ABCA4
protein functions in the recycling of all-trans
retinal (20,59-60). ABCA4 contains two extended
extracellular loops that are evolutionarily
conserved but lack any apparent function. Genetic
studies involving patients with inherited macular
degenerations, demonstrate mutations in these
domains clearly impair ABCA4 transporter
function, thereby establishing important role(s) of
the ECDs (19,23,50-51,54).
The Second Extracellular Domain of ABCA4
Possesses a Highly Ordered and Stable
Conformation. In order to delineate its role in
ABCA4 transporter function, we first explored the
structure and conformational features of the ECD2
domain and alterations due to disease-associated
mutations. Analysis of the CD spectral data using
the K2D2 method indicated that the wild type
polypeptide possessed a highly ordered structure
that has a reasonably high α-helical content in
addition to β-sheet and extended structures.
Depending on the mutation, ECD2 protein
conformation changed only slightly or very
drastically. Thus, CD analysis provided a method
for monitoring conformational changes due to
macular
degenerative
disease
associated
mutations.
Unfortunately despite an intensive search,
very little collective information correlating the
severity and age of onset with a given mutation is
available, making it difficult for us to correlate the
observed structural defects with a given clinical
phenotype.
8

Using tryptophan fluorescence emission
spectrum, we have investigated the binding of
ECD2 domain to retinal, and examined how this
binding is affected in disease associated mutants.
When all-trans retinal was added to ECD2
polypeptide, dose-dependent attenuation of its
tryptophan fluorescence was observed (Fig. 7).
Titration with all-trans retinal was used to
evaluate the binding quantitatively, and the ECD2
polypeptide bound all-trans retinal with
reasonably high affinity, Kd, app of 1.3 x 10-7 M
(Fig. 8 and Table 3). The binding appeared highly
specific as attenuation of tryptophan fluorescence
by 11-cis retinal was significantly lower (Fig 9).
The affinity of interaction for all-trans retinal
observed in our experimental system is
approximately ~30-fold higher than that
previously reported by Beharry et al. (64). Using
fluorescence anisotropy we were able to
demonstrate direct interaction of the ECD2
polypeptide and quantitate its interaction. The KD
of 4 ± 1.3 X 10-7 is approximately 2-fold higher
than that derived from the intrinsic tryptophan
fluorescence. This small difference may be
attributed to the fact that the two approaches are
assessing retinal interaction through the
measurement of two different parameters: one
examines the change in ECD2 protein structure as
using tryptophan environment as a reporter, the
other approach measuring the fluorescence
anisotropy of all-trans retinal itself.
The locations of the seven tryptophan
residues are indicated on the multiple sequence
alignment shown in Figure 2. These residues are
strictly conserved and are distributed across the
domain. The emission maxima and quantum yields
of tryptophan residues vary widely between
proteins and can be a function of protein structure
(37{Lugo, 2009 #4375{Lakowicz, 2006 #1086)}.
A given protein conformation may contribute to
specific protein environments that quench a given
tryptophan residue or residues. All-trans retinal
is a relatively large, hydrophobic molecule and its
binding site would need to be hydrophobic as well.
Indeed, studies examining retinoid binding
properties of the nematode ABA-1 allergen
protein, describe the major structural role of
tryptophan in providing a hydrophobic binding site
for the ligand (68). A possible explanation for the
observed decrease in fluorescence would be that
the ECD2 domain undergoes a conformational

Influence of Stargardt Disease Associated
Mutations on ECD2 Domain Secondary Structure:
Of the three mutants examined here, the R1443H
mutation appeared to be the most severe in terms
of its influence on the secondary structure of
ECD2. As a consequence of this mutation, the
ECD2 polypeptide appeared to lose the majority of
its α-helical secondary structure (Fig. 5). Very
little change was observed in the protein’s
structure in response to temperature (Fig. 6D),
suggesting that the polypeptide was highly
disordered. A minimal change in the CD spectrum
was observed with the W1409L mutation. This
mutant appeared to have secondary structural
parameters which were comparable to that of the
wild type ECD2 polypeptide. In addition, only a
small increase in Tm was observed from the
thermal melting curves. This small increase may
be due to the decrease in relative hydrophobicity
associated with the WL mutation, such as that
described by Kotik and coworkers in their studies
which examining the role of tryptophan residues in
the structural and thermal stability of lactate
dehydrogenase (61).
The C1488R mutation
appeared to be intermediate in nature with respect
to its influence on the ECD2 structure. Based on
the CD analysis of the protein, it appeared to have
lower α-helix content. Interestingly, a major
increase in the Tm obtained from the thermal
melting profile of the CD spectra was observed.
The substitution of a charged residue, arginine for
cysteine, may provide enhanced thermal stability
to the structure, perhaps through ionic interactions.
Liao and coworkers report similar increases in Tm
upon introduction of charged residues into porcine
αβ-crystallin (62). ECD2 Domain Interacts
Specifically with all-trans Retinal: Several lines of
investigation support the hypothesis that all-trans
retinal, the product of the visual transduction
cycle, is the substrate of ABCA4 (63-65).
Physiologically, studies of ABCA4 knockout mice
show elevated levels of all-trans retinal and the
protonated Schiff’s base, N-retinylidene-PE, as
well as the di-retinal pyridinium compound A2E
in the retinal pigment epithelium (65-67).
Together these studies strongly support all-trans
retinal as the substrate for ABCA4. However, at
present no assay for ATP dependent transport by
ABCA4 has been developed and which region of
the ABCA4 molecule interacts specifically with
the substrate remains to be identified.
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change during retinal binding, in order to create a
hydrophobic pocket. The conformational change
causes a change in the environment of the
tryptophan residues, thereby leading to the
observed decrease in fluorescence. This
These studies indicate that the ECD2
domain is involved in binding all-trans retinal in
its transport across the ROS disc membrane.
ECD2 may also be involved in the transport of
retinal derivatives, such as N-retinylidinephosphatidyl ethanolamine, since the Shiff’s base
present in these compounds is formed from the
aldehyde functional group of all-trans retinal.
Influence of Stargardt Disease Associated
Mutations on ECD2 Interaction with all-trans
Retinal: To date the biochemical observables
measured for mutant ABCA4 proteins have been
restricted to ATP binding and hydrolysis; protein
localization of heterologously expressed protein in
cell culture, and interaction of the nucleotide
binding domains (32,67,69-72).
All mutants
investigated demonstrated decreases in their
affinity of interaction with all-trans retinal, based
on their ability to attenuate intrinsic tryptophan
fluorescence (Figs. 7 & 8). In the case of mutant
R1443H a large decrease in the binding affinity
was observed, with a >250-fold increase in Kd
(Fig. 8 and Table 3). Less dramatic changes were
seen with the other mutants investigated in this
study; with a 5-8-fold increase in Kd for W1408L
and C1488R respectively. With mutant R1443H,
apparent lack of interaction with all-trans retinal
was observed. Direct analysis of mutant R1433H
interaction confirmed impairment of all-trans
retinal binding by this mutant, as shown by the
inability to achieve saturation (Fig. 10B).
Interestingly, the functional alterations in all-trans
retinal interaction were mirrored by the structural
alterations in this domain as determined by CD
spectroscopic analysis of their conformations. The
conformation of R1443H was strikingly different
from that of wt ECD2, and appeared refractory to
changes in temperature. It is likely that its
inability to interact with all-trans retinal has a
basis in its abnormal structural features. Likewise,
the relatively moderate structural changes of
W1408L and C1488R also correlated with more
moderate changes in interaction with all-trans
retinal as compared to the wild type ECD2.
This report demonstrates that the ECD2
domain of ABCA4 has a highly ordered and stable

secondary structure, which appears to undergo
conformational change in response to its specific
interaction with its putative substrate all-trans
retinal. Disease associated mutations in this
domain were observed to influence the secondary
structure and all-trans retinal binding affinity.
Further studies of each of the ABCA4 domains are
required to elucidate the mechanism of retinal
transport by this complex and physiologically
important ABC transporter.
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FIGURE LEGENDS
Fig. 1. Predicted Structural Organization of ABCA4 and Its Domains. Pictorial representation
showing the cytoplasmic, extracellular and transmembrane domains of ABCA4 protein. The
domains were defined based on current topological models of ABCA4 (24), and are as follows:
NDB1 aa 854 - 1375, NBD2 aa 1898-2273, ECD1 aa 62-646 and ECD2 aa 1395-1680.
Fig. 2. Sequence Alignment of ECD2 Domains of ABCA4 Proteins Derived from Several
Vertebrate Species. The amino acid sequences of several vertebrate organisms were obtained
from NCBI; H. sapiens (human), M. faccicularis (crab eating macaque), B. taurus (bovine), C.
familiaris (dog), M. musculus (mouse) and X. laveis (African clawed frog), and were aligned
using ClustalW. The amino acid residue number for each protein is indicated at the beginning of
13

each sequence. The alignment is color coded to indicate chemical characteristics of a given
amino acid: red, basic; blue hydrophobic; green, hydrophilic; orange, neutral, pink, acidic, and
light green, proline. Missense mutations examined in this study are enclosed by boxes.
Fig. 3. Purification of ABCA4-ECD2 Protein. (A) Overexpression of ABCA4-ECD2
Polypeptide. SDS-PAGE analysis of the overexpressed ECD2 polypeptide in E. coli. Expression
of the recombinant protein was carried out as described in “Methods” in the presence of 0.25 mM
IPTG. Equal amounts of cells before and after induction were analyzed. Lane 1, protein
molecular mass standard; lane 2, uninduced RIPL (DE3)/pET30b ECD2 cell lysate; and lane 3,
cell lysate from IPTG induced RIPL (DE3)/pET30b ECD2. (B) ECD2 Polypeptide Purified by SProtein Agarose Chromatography. SDS-PAGE of S-protein agarose purification of ECD2. An
aliquot (corresponding to 10 µg) of purified ECD2 was analyzed on a 5 →18% SDS PAGE gel
which was stained with Coomassie Blue R250 following electrophoresis. (C) ECD2 Wild Type
and Mutant Purified Refolded Polypeptides. Approximately 4.5 µg of the respective purified,
refolded protein was loaded onto a 5–18% SDS-PAGE, which was stained with Coomassie Blue
R-250 following electrophoresis. As shown the ABCA4-ECD2 protein migrated with predicted
molecular mass of ~34 kDa.
Fig. 4. Circular Dichroism Spectra of Native and Refolded ABCA4-ECD2 Polypeptides.
Comparative far-UV (200-250 nm) CD spectra of ECD2 from S-tag agarose and refolding-based
purifications. The concentration of ECD2 polypeptide was 10 µM in 10 mM NaPO4, pH 7.5, 100
mM NaCl. The spectra were acquired with a 5 mm path length cuvette, at 25°C; scans were
collected five times and averaged. Buffer spectra were always subtracted. Native-S-protein
agarose chromatography (dashed line), refolded (solid line).
Fig. 5. Circular Dichroism Spectra of Wild Type and Mutant ABCA4-ECD2 Polypeptides. CD
spectra were collected from highly purified homogenous preparations of recombinant wild type
and mutant ECD2 polypeptides. Far-UV (200-250 nm) CD spectra were acquired with a 5 mm
path length cuvette. The concentration of ECD2 polypeptides were 10 µM in 10 mM KPO4, pH
7.5, 100 mM NaCl. The spectra were acquired with a 5 mm path length cuvette, at 25°C; scans
were collected five times and averaged. Buffer spectra were always subtracted.
Fig. 6. Circular Dichroism Spectra of Wild Type and Mutant ABCA4-ECD2 Polypeptides as a
Function of Temperature. CD spectra were acquired (200-250 nm) over the range of 20-80°C, at
10°C increments, using a resolution of 0.2°C. The concentration of ECD2 wild type and mutant
polypeptides were 10 µM in 10 mM NaPO4, pH 7.5, 100 mM NaCl. The spectra were acquired
with a 5 mm path length cuvette, at 25°C; scans were collected five times and averaged. Buffer
spectra were always subtracted. (A) wild type ECD2; inset: ellipticity at 220 nm was monitored
over the range of 20-80°C and the Tm was determined from the inflection points of data fitted to
sigmodial curve.; (B) W1408L; (C) C1488R , and (D) R1443H.
Tryptophan Fluorescence Intensity of Wild-Type and Mutant ABCA4-ECD2
Fig. 7.
Polypeptides in the Presence of all-trans Retinal. Fluorescence spectra of wild-type and mutant
ECD2 polypeptides were collected at 25°C in the presence of increasing amounts of all-trans
retinal over the concentration range 0-15 µM as indicated. The concentration of ECD2
polypeptide was 3 µM in 10 mM NaPO4, pH 7.5, 100 mM NaCl. The scans were conducted in
triplicate and the data were analyzed by least-squares regression analysis using Graph Pad
PRISM software.
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Fig. 8. Ligand Binding Analysis by Monitoring Changes in Intrinsic Tryptophan Fluorescence in
the Presence of all-trans Retinal. Data obtained from the fluorescence spectra of wild-type and
mutant ECD2 polypeptides described in Figure 7 were analyzed in terms of percent change in
intensity versus log of the all-trans retinal concentration. (
) ECD2 WT; (
) R1443H; (
)
W1408L; (
) C1488R.
Fig. 9. Tryptophan Fluorescence Intensity of Wild-Type ECD2 in the Presence of 11-cis Retinal.
Fluorescence spectra of wild-type ECD2 polypeptide were collected at 25°C in the presence of
increasing amounts of 11-cis retinal over the concentration range 0-10 µM as indicated. The
concentration of ECD2 polypeptide was 3 µM in 10 mM NaPO4, pH 7.5, 100 mM NaCl. The
scans were conducted in triplicate and the data were analyzed by least-squares regression analysis
using Graph Pad PRISM software.
Fig. 9. Fluorescence Anisotropy Analysis of ECD2 proteins with the all-trans Retinal. (A)
Emission spectrum of 100 nM all-trans retinal (ATR). Excitation was 310 nm and emission was
scanned over a range of 370 to 570 nm (B) Anisotropy titrations using wild-type ECD2 () and
the R1433H mutant (). The titrations were carried out as described under “Materials and
Methods.” Fluorescence anisotropy measurements were collected for ATR•ECD2 protein
samples formed by the stepwise addition of ECD2 protein to 100 nM ATR. All samples were
incubated at room for 2–3 min with constant stirring before taking anisotropy measures. The data
were fitted with BIOEQS using a simple binding model (monomer) for all-trans retinal binding to
wild-type and R1433H proteins NBD1 proteins.
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Table 1: Stargardt Disease Associated Mutations Occurring in the ECD2 Domain
Investigated in this Study.

Mutation

Base Change

Mutagenesis Primer

R1443H

CGC4328CAC

5'-CAGGCTTTGGCAACCACTGAAGGAAGGGTGGCTTC-3'

W1408L

TGG4221TTG

5'-ACCCTTCACCCCTTGATATGGGCAGCAGTACACCTTC-3'

C1488R

TGC4462CGC

5'-AACCCTTCACCATCCCGCAGGTGCAGCACCAGGGAGAAG-3'
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Table 2: Summary of the Secondary Structure for ECD2 Polypeptide.

Secondary Stucture
α-helix

β-sheet

Extended-coil

Affinity Purified

0.27

0.20

0.53

Refolded

0.25

0.20

0.55

ECD2 protein
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Table 3: Summary of Secondary Structure Analysis and Binding Constants for the ABCA4ECD2 WT and Mutant Polypeptides Based on CD Data Analyzed by K2D2 Method (42-43).

Genotype

α-helix

β-sheet

Random coil

Tm (°C)

Kd (M)

Wild-type

0.25

0.20

0.55

49.7

1.3 x 10-7

R1433H

0.11

0.39

0.50

n.d.

n.d.

W1408L

0.23

0.24

0.53

57.1

8.1 x 10-7

C1488R

0.20

0.27

0.53

66.7

6.7 x 10-7
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